Teduglutide

Teduglutide is a recombinant analog of glucagon-like peptide-2 (GLP-2) approved for adults with short bowel syndrome who are dependent on parenteral support. It promotes intestinal adaptation and increases nutrient absorption. Unlike native GLP-2, it has an extended half-life.

PubMed results: 341 · Human studies: 241 · Animal studies: 261

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Doses studied in published research. Information presented for research purposes only, not a recommendation for human use.

• Subcutaneous — standard range 0.05 mg/kg, Once daily

1.3 hours (high confidence)

• NCT03442972 — Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids (PHASE2 / PHASE3), status: COMPLETED. Indications: Hyperlipidemias
• NCT04733066 — Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis, status: UNKNOWN. Indications: Short Bowel Syndrome, Intestinal Failure
• NCT03422666 — Plasma Lipoprotein Response to Glucagon-like Peptide-2 (PHASE2 / PHASE3), status: COMPLETED. Indications: Hyperlipidemias
• NCT05027308 — A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older (PHASE3), status: COMPLETED. Indications: Short Bowel Syndrome
• NCT02980666 — Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support (PHASE3), status: COMPLETED. Indications: Short Bowel Syndrome
• NCT03716115 — Therapeutic Approaches to Malnutrition Enteropathy (PHASE2), status: COMPLETED. Indications: Severe Acute Malnutrition
• NCT02099084 — Short Bowel Syndrome and Teduglutide Versus Placebo (PHASE4), status: COMPLETED. Indications: Short Bowel Syndrome
• NCT02889393 — Teduglutide for Enterocutaneous Fistula (ECF) (PHASE2), status: COMPLETED. Indications: Postoperative Fistula
• NCT03534661 — L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release (PHASE2 / PHASE3), status: COMPLETED. Indications: Hyperlipidemias
• NCT04290429 — Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients (EARLY_PHASE1), status: COMPLETED. Indications: Graft Versus Host Disease
• NCT05561647 — A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey), status: RECRUITING. Indications: Short Bowel Syndrome (SBS)
• NCT01209351 — Effect of Teduglutide on Gastric Emptying in Healthy Subjects (PHASE1), status: COMPLETED. Indications: Healthy Volunteers
• NCT04877431 — A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease, status: COMPLETED. Indications: Short Bowel Syndrome
• NCT01028924 — Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers (PHASE1), status: COMPLETED. Indications: Healthy
• NCT03268811 — A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 (PHASE3), status: COMPLETED. Indications: Short Bowel Syndrome
• NCT03596164 — An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 (PHASE3), status: COMPLETED. Indications: Short Bowel Syndrome
• NCT03663582 — Study of Teduglutide in Japanese Participants With Short Bowel Syndrome (PHASE3), status: COMPLETED. Indications: Short Bowel Syndrome
• NCT05023382 — A Study of Teduglutide in Japanese People With Short Bowel Syndrome, status: RECRUITING. Indications: Short Bowel Syndrome
• NCT04916665 — Bridging Intestinal Failure With Teduglutide - a Case Report, status: COMPLETED. Indications: Short Bowel Syndrome
• NCT04832087 — Pediatric Teduglutide Registry, status: COMPLETED. Indications: Short Bowel Syndrome